Skip to content
PharmaManufacturingIQ

Holistic IP strategy is needed for ‘off-the-shelf’ CAR T cell therapies

With so much investor interest surrounding the potential of allogeneic CAR T cell therapies, the stakes are high for innovators to ensure that their inventions are robustly protected from the start.

By PharmaManufacturing IQ Staff
Holistic IP strategy is needed for ‘off-the-shelf’ CAR T cell therapies
Published: | 3 min read
Share to X Share to Bluesky Share to Facebook Share to LinkedIn Share by email

With so much investor interest surrounding the potential of allogeneic CAR T cell therapies, the stakes are high for innovators to ensure that their inventions are robustly protected from the start. Justin Wilson, partner and cell & gene therapy sector specialist at Withers & Rogers discusses.

Cell and Gene Therapies

Sign up to our newsletter

The week's biggest stories from this industry, direct to your inbox.

Personal information